In this issue of Circulation, Cosentino and colleagues1 report the results of prespecified analyses from the VERTIS-CV trial (Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial) of the efficacy of the sodium glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin on heart failure (HF)–related events in patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
The 8246 patients enrolled in VERTIS-CV were at least 40 years of age (mean age 64 years), and all had T2D with established atherosclerotic cardiovascular disease (coronary artery disease [76%], cerebrovascular disease [23%], and peripheral arterial disease [19%]). The mean duration of T2D was 12.9 years at baseline, with an average glycohemoglobin of 8.3%.2
The Table compares the main cardiovascular outcome trials for the SGLT2 inhibitors: the patients enrolled in VERTIS-CV are most similar to those in the EMPA-REG OUTCOME study (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients),3 which also enrolled patients with T2D with established atherosclerosis, but studied empagliflozin.
Reference link- https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.050512
